BridgeBio Pharma, Inc. (BBIO) announced strategic financing from Blue Owl Capital and Canada Pension Plan Investment Board, through a wholly owned subsidiary of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion. The financing includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis. It also includes a $450 million credit facility from Blue Owl that refinances existing senior secured credit, extending maturity from 2026 to 2029. The agreement with Blue Owl provides for the possibility of additional incremental facilities of up to $300 million of credit.
Brian Stephenson, CFO of BridgeBio, said: "Our newly strengthened balance sheet will enable us to serve ATTR-CM patients with a well-resourced launch of acoramidis, as well as patients with genetic diseases more broadly with multiple Phase 3 readouts for blockbuster indications anticipated over the next few years."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.